ArticleNeurochemical research2025
Dantrolene Protects Hippocampal Neurons Against Amyloid-β₁₋₄₂-Induced Calcium Dysregulation and Cell Death.
Article in Neurochemical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Screening of cell-type-specific meta-programs for drug repurposing in Alzheimer's disease.Briefings in bioinformatics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The accumulation of amyloid-β₁₋₄₂ (Aβ₁₋₄₂) in the brain is a hallmark of Alzheimer's disease (AD), contributing to intracellular calcium dysregulation and neuronal death. Ryanodine receptors (RyRs), located in the endoplasmic reticulum (ER), play a pivotal role in intracellular calcium release and homeostasis. In this study, we employed an in vitro model of AD using cultured rat hippocampal neurons treated with Aβ₁₋₄₂ to investigate the effects of dantrolene, a RyR antagonist, on calcium signaling and neuronal viability. Dantrolene significantly reduced basal cytosolic calcium levels and attenuated stimulus-induced calcium transients in response to depolarizing solution, electrical field stimulation, and caffeine application. These findings indicate that dantrolene stabilizes intracellular calcium signaling by limiting calcium release from ER stores. Furthermore, co-application of dantrolene with Aβ₁₋₄₂ increased neuronal survival from 26 to 76% and significantly reduced the proportions of apoptotic and necrotic cells. These results demonstrate that RyRs contribute to calcium overload and neurotoxicity under AD-like conditions and that dantrolene effectively counteracts Aβ₁₋₄₂-induced calcium dysregulation. Altogether, our findings support the calcium hypothesis of AD and highlight dantrolene as a potential disease-modifying agent targeting ER-mediated calcium homeostasis.
Indexed as
Identifiers
40504441What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.